Printer Friendly
The Free Library
23,383,293 articles and books


Twinlab Corporation Issues Statement in Response to FDA Warning Letter Concerning Androstenedione.

HAUPPAUGE, N.Y., March 12 /PRNewswire/ -- Twinlab Corporation, a wholly-owned subsidiary of IdeaSphere, Inc. today issued the following statement in response to the US Food and Drug Administration's warning letter to Twinlab Corporation concerning products containing androstenedione, or "andro":
 Twinlab Corporation respectfully disagrees with the conclusions
 drawn in the FDA warning letter and is in the process of preparing
 an appropriate response that will be submitted within the allowable
 response period.

 We believe that Twinlab androstenedione products are safe and
 effective if used as directed. When IdeaSphere, Inc. acquired the
 Twinlab assets in December 2003, the decision was made in view of
 the declining market for androstenediol/androstenedione products
 and the availability of new ingredients not to offer these products
 on a go-forward basis. In support of that decision, IdeaSphere Inc.
 did not acquire any assets related to androstenediol products. It
 did acquire pre-existing inventory of Twinlab's Andro Fuel product,
 which contains androstenedione, however this is residual inventory
 that is being phased out of the market.

 Twinlab is currently manufacturing and will commence selling a new
 performance product, Andro Nitrate 4 Fuel, in April 2004. This
 product contains no androstenediol and no androstenedione. "Andro"
 is a longstanding Twinlab brand name drawing its identity from the
 Greek root meaning "male" or "masculine," and will be retained for
 that reason.

 IdeaSphere Inc. and Twinlab Corporation share the FDA's commitment
 to science and safety - we are science-focused and research-driven.
 Notwithstanding this disagreement, Twinlab remains committed to the
 principle that by working hand in hand with the FDA on this and
 other matters, Twinlab, the industry, and ultimately the consumer
 all win.

 About Twinlab



Twinlab, based in Hauppauge, NY, is the leading manufacturer and marketer of high quality, science-based, nutritional supplements, including a robust line of vitamins, minerals, specialty supplements, herbs, teas and sports nutrition products.

About IdeaSphere, Inc.

IdeaSphere, Inc., with offices in New York, NY, Hauppauge, NY, Grand Rapids, Michigan, and American Fork, Utah, is the champion of the Wellness Revolution. A purpose-built, vertically integrated health and wellness company, it provides total wellness solutions through its holdings, which include leaders in wellness products, content and services. IdeaSphere's family of companies includes Twinlab Corporation; Rebus LLC, and iVillage Solutions.
 Contact: Ross A. Anderson, IdeaSphere, Inc.
 631-467-3140 ext. 8324
 randerson@ideasphereinc.com

 Alan Ampolsk, PR21
 212-299-8953
 alan.ampolsk@pr21.com



CONTACT: Ross A. Anderson, of IdeaSphere, Inc., +1-631-467-3140 ext. 8324, randerson@ideasphereinc.com; or Alan Ampolsk of PR21, +1-212-299-8953, alan.ampolsk@pr21.com, for Twinlab Corporation
COPYRIGHT 2004 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Mar 12, 2004
Words:412
Previous Article:Hobbs Company Uses MEP to Write Quality Manual.
Next Article:Monadnock Community Bank Announces Plan to Reorganize into a Mutual Holding Company and Conduct Minority Stock Offering.
Topics:



Related Articles
Gliatech Announces FDA Alert.
Gliatech Reports Progress With FDA.
CRN Supports FDA Action on Androstenedione Under DSHEA; - Reaffirms support of Biden/Hatch Legislation -.
IdeaSphere Launches Integrative Health Solutions(SM) Platinum Plus for Business MasterCard; MBNA Card Designed to Support the Needs of Natural/Health...
Biopure Updates Hemopure(R) Regulatory Status Following FDA Meeting.
Cyberonics Receives FDA Warning Letter Regarding the Good Manufacturing Practice Requirements of the Quality System Regulation for Medical Devices.
Ranbaxy, Statement on FDA Letters.
Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters